Pfizer to pay $35M to settle drug marketing case

Pfizer will pay $35 million to resolve allegations by 42 states that its subsidiary, Wyeth Pharmaceuticals, illegally marketed an organ transplant drug for unapproved uses.

The states' attorneys general said Wednesday that Wyeth, which Pfizer bought in 2009, trained to encourage doctors to prescribe Rapamune for uses other than preventing rejection of transplanted kidneys.

Rapamune was approved in 1999 for use in . Promoting drugs for uses not cleared by the Food and Drug Administration is illegal.

Pfizer agreed to pay nearly $491 million in July 2013 to resolve a similar investigation by the Department of Justice.

Pfizer said in a statement that the alleged activity occurred before it acquired Wyeth. The company did not admit any wrongdoing or liability as part of the settlement.

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Pfizer to pay $491M to resolve drug marketing case (Update)

Jul 30, 2013

The U.S. Justice Department said Tuesday that drugmaker Pfizer Inc. will pay almost $491 million to resolve an investigation into illegal marketing of the organ transplant drug Rapamune by a company Pfizer later acquired.

Endo Health to pay $192.7M in gov't settlement

Feb 22, 2014

Endo Health will pay almost $193 million to resolve claims that it improperly marketed the shingles treatment Lidoderm for unapproved uses like treating lower back pain.

Pfizer will buy NextWave Pharma for up to $700M

Oct 22, 2012

(AP)—Pfizer said Monday it will buy NextWave Pharmaceuticals Inc., a company that makes a liquid attention deficit hyperactivity disorder drug, in a deal worth as much as $700 million.

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.